BioSpace57m
Emalex Heads to FDA After Phase III Tourette Syndrome Win
In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...
ENDPOINTS NEWS18h
Chica­go biotech Emalex says it cleared a Phase 3 for Tourette syn­drome, will seek FDA ap­proval
Emalex Biosciences said its daily oral tablet helped reduce relapses for children and adults with Tourette syndrome in a ...
FierceBiotech21h
Emalex dopamine blocker stops Tourette syndrome relapse in phase 3 win
Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...
Le Lézard23h
Board-Certified Physicians Celia Garner, MD, and Nicholas G. Hanson, MD, Open MDVIP-Affiliated Practices in Salt Lake City
MDVIP, the market leader in membership-based healthcare with a network of over 1,300 primary care physicians nationwide, has ...
Le Lézard23h
Zebra Technologies to Present at the Morgan Stanley Technology, Media & Telecom Conference
Zebra Technologies Corporation , a global leader in digitizing and automating frontline workflows, today announced that the company will present at the Morgan Stanley Technology, Media & Telecom ...
Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study
Emalex Biosciences met primary and secondary endpoints in its Phase 3 registrational trial of ecopipam for patients with ...